Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 34, 2016, Pages 9593-9598

  Bassil, Fares ^a,b   Fernagut, Pierre Olivier ^a,b   Bezard, Erwan ^a,b   Pruvost, Alain ^c   Leste Lasserre, Thierry ^d   Hoang, Quyen Q ^e   Ringe, Dagmar ^f   Petsko, Gregory A ^f,g   Meissner, Wassilios G ^a,b,h  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d INSTITUT FRANÇOIS MAGENDIE   (France)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f BRANDEIS UNIVERSITY   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h HÔPITAL PELLEGRIN   (France)

Author keywords

Alpha synuclein; Caspase 1; Multiple system atrophy; Truncation

Indexed keywords

ALPHA SYNUCLEIN; BELNACASAN; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; PLACEBO; TYROSINE 3 MONOOXYGENASE; 1-(2-((1-(4-AMINO-3-CHLOROPHENYL)METHANOYL)AMINO)-3,3-DIMETHYLBUTANOYL)PYRROLIDINE-2-CARBOXYLIC ACID; 4 AMINOBENZOIC ACID DERIVATIVE; DIPEPTIDE; PROTEIN AGGREGATE; SNCA PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN NERVE CELL; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG TOLERABILITY; EPILEPSY; GENE EXPRESSION; IN VIVO STUDY; MOTOR DYSFUNCTION; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN AGGREGATION; QUANTITATIVE ANALYSIS; SHY DRAGER SYNDROME; SUBSTANTIA NIGRA; SUBSTANTIA NIGRA PARS COMPACTA; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NERVE CELL; PATHOLOGY; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ALPHA-SYNUCLEIN; ANIMALS; CASPASE 1; CLINICAL TRIALS AS TOPIC; CORPUS STRIATUM; DIPEPTIDES; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HUMANS; MICE; MICE, TRANSGENIC; MULTIPLE SYSTEM ATROPHY; NEURONS; OLIGODENDROGLIA; PARA-AMINOBENZOATES; PROTEIN AGGREGATES; PROTEOLYSIS; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 84983651724     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1609291113     Document Type: Article

References (64)

1. Gilman S, et al. (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71(9):670-676.
2. Spillantini MG, et al. (1998) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett 251(3):205-208.
3. Papp MI, Kahn JE, Lantos PL (1989) Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 94(1-3):79-100.
4. Fauvet B, et al. (2012) α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem 287(19):15345-15364.
5. Rochet JC, Conway KA, Lansbury PT, Jr (2000) Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. Biochemistry 39(35):10619-10626.
6. Lashuel HA, Overk CR, Oueslati A, Masliah E (2013) The many faces of α-synuclein: From structure and toxicity to therapeutic target. Nat Rev Neurosci 14(1):38-48.
7. Muntané G, Ferrer I, Martinez-Vicente M (2012) α-synuclein phosphorylation and truncation are normal events in the adult human brain. Neuroscience 200:106-119.
8. Cremades N, et al. (2012) Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell 149(5):1048-1059.
9. Auluck PK, Caraveo G, Lindquist S (2010) α-Synuclein: Membrane interactions and toxicity in Parkinson's disease. Annu Rev Cell Dev Biol 26:211-233.
10. Winner B, et al. (2011) In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci USA 108(10):4194-4199.
11. Li W, et al. (2005) Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci USA 102(6):2162-2167.
12. Liu CW, et al. (2005) A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: Implications for pathogenesis of Parkinson disease. J Biol Chem 280(24):22670-22678.
13. Hoyer W, Cherny D, Subramaniam V, Jovin TM (2004) Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro. Biochemistry 43(51):16233-16242.
14. Ulusoy A, Febbraro F, Jensen PH, Kirik D, Romero-Ramos M (2010) Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology. Eur J Neurosci 32(3):409-422.
15. Fernagut PO, et al. (2014) Multiple system atrophy: A prototypical synucleinopathy for disease-modifying therapeutic strategies. Neurobiol Dis 67:133-139.
16. Wang W, et al. (2016) Caspase-1 causes truncation and aggregation of the Parkinson disease-associated α-synuclein. Proc Natl Acad Sci USA 113:9587-9592.
17. Boxer MB, Shen M, Auld DS, Wells JA, Thomas CJ (2010) A small molecule inhibitor of Caspase 1, probe reports from the NIH Molecular Libraries Program (NIH, Bethesda, MD).
18. Wannamaker W, et al. (2007) (S)-1-((S)-2-[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxotetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J Pharmacol Exp Ther 321(2):509-516.
19. Noe FM, et al. (2013) Pharmacological blockade of IL-1β/IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsy. Neurobiol Dis 59:183-193.
20. Vertex P (2011) Vertex Announces Completion of Phase 2 Study of VX-765 in People with Epilepsy who did not Respond to Previous Treatment. Available at investors.vrtx.com/releasedetail.cfm?ReleaseID=555967.
21. Fernagut PO, et al. (2014) Age-related motor dysfunction and neuropathology in a transgenic mouse model of multiple system atrophy. Synapse 68(3):98-106.
22. Kahle PJ, et al. (2002) Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep 3(6):583-588.
23. Stefanova N, et al. (2005) Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. Am J Pathol 166(3):869-876.
24. Fernagut PO, Tison F (2012) Animal models of multiple system atrophy. Neuroscience 211:77-82.
25. Stefanova N, Tison F, Reindl M, Poewe W, Wenning GK (2005) Animal models of multiple system atrophy. Trends Neurosci 28(9):501-506.
26. Stefanova N, et al. (2007) Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy: Implications for multiple system atrophy. Mov Disord 22(15):2196-2203.
27. Spillantini MG, Goedert M (2000) The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci 920:16-27.
28. Recasens A, Dehay B (2014) Alpha-synuclein spreading in Parkinson's disease. Front Neuroanat 8:159.
29. Recasens A, et al. (2014) Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol 75(3):351-362.
30. Conway KA, et al. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy. Proc Natl Acad Sci USA 97(2):571-576.
31. Savolainen MH, et al. (2014) The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse. Neurobiol Dis 68:1-15.
32. Bieschke J, et al. (2010) EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc Natl Acad Sci USA 107(17):7710-7715.
33. Levin J, et al. (2014) The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset. Acta Neuropathol 127(5):779-780.
34. Masliah E, et al. (2011) Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One 6(4):e19338.
35. Myöhänen TT, et al. (2012) A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease. Br J Pharmacol 166(3):1097-1113.
36. Crowther RA, Jakes R, Spillantini MG, Goedert M (1998) Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Lett 436(3):309-312.
37. Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA (2000) Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci USA 97(9):4897-4902.
38. Murray IV, et al. (2003) Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry 42(28):8530-8540.
39. Dufty BM, et al. (2007) Calpain-cleavage of alpha-synuclein: Connecting proteolytic processing to disease-linked aggregation. Am J Pathol 170(5):1725-1738.
40. Periquet M, Fulga T, Myllykangas L, Schlossmacher MG, Feany MB (2007) Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci 27(12):3338-3346.
41. Michell AW, et al. (2007) The effect of truncated human alpha-synuclein (1-120) on dopaminergic cells in a transgenic mouse model of Parkinson's disease. Cell Transplant 16(5):461-474.
42. Mishizen-Eberz AJ, et al. (2003) Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro. J Neurochem 86(4):836-847.
43. Tsigelny IF, et al. (2007) Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein. FEBS J 274(7):1862-1877.
44. Diepenbroek M, et al. (2014) Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic mice. Hum Mol Genet 23(15):3975-3989.
45. Games D, et al. (2014) Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models. J Neurosci 34(28):9441-9454.
46. Daher JP, et al. (2009) Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons. Mol Neurodegener 4:34.
47. Tofaris GK, et al. (2006) Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): Implications for Lewy body disorders. J Neurosci 26(15):3942-3950.
48. Gai WP, Power JH, Blumbergs PC, Culvenor JG, Jensen PH (1999) Alpha-synuclein immunoisolation of glial inclusions from multiple system atrophy brain tissue reveals multiprotein components. J Neurochem 73(5):2093-2100.
49. Tong J, et al. (2010) Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: A comparative investigation. Brain 133(Pt 1):172-188.
50. Campbell BC, et al. (2001) The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. J Neurochem 76(1):87-96.
51. Baba M, et al. (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 152(4):879-884.
52. Choi DH, et al. (2011) Role of matrix metalloproteinase 3-mediated alpha-synuclein cleavage in dopaminergic cell death. J Biol Chem 286(16):14168-14177.
53. Kim KS, et al. (2012) Proteolytic cleavage of extracellular α-synuclein by plasmin: implications for Parkinson disease. J Biol Chem 287(30):24862-24872.
54. Sung JY, et al. (2005) Proteolytic cleavage of extracellular secreted alpha-synuclein via matrix metalloproteinases. J Biol Chem 280(26):25216-25224.
55. Bassil F, et al. (2015) Region-specific alterations of matrix metalloproteinase activity in multiple system atrophy. Mov Disord 30(13):1802-1812.
56. Franchi L, Eigenbrod T, Muñoz-Planillo R, Nuñez G (2009) The inflammasome: A caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 10(3):241-247.
57. Maroso M, et al. (2011) Interleukin-1β biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice. Neurotherapeutics 8(2):304-315.
58. Fleming SM, et al. (2004) Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci 24(42):9434-9440.
59. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162(1):156-159.
60. Bustin SA, et al. (2009) The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55(4):611-622.
61. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25(4):402-408.
62. Dehay B, et al. (2012) Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc Natl Acad Sci USA 109(24):9611-9616.
63. Mingam R, et al. (2008) In vitro and in vivo evidence for a role of the P2X7 receptor in the release of IL-1 beta in the murine brain. Brain Behav Immun 22(2):234-244.
64. Fernagut PO, et al. (2007) Behavioral and histopathological consequences of paraquat intoxication in mice: Effects of alpha-synuclein over-expression. Synapse 61(12):991-1001.